IRCT20190914044766N1招募中3 期
Graft versus host disease prevention/reduction by microbiome and patient blood management in allogeneic hematopoietic stem cell transplant patients
High Institute for Research and Education in Transfusion Medicine0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 50 years（—）
- 性别
- All
入选标准
- •Candidates for allogeneic bone marrow transplant who have been referred for transplantation to Taleghani Hospital for treatment of blood malignancies
- •Age 20 to 50 years
- •The source of the transplanted tissue of all patients is peripheral blood stem cells
- •HLA transplanted tissue to be fully compatible with patient HLA (fully compatible with primary HLA A , B and DR-B1 )
- •The prophylaxis diet should be the same to prevent GVHD
- •All patients use irradiated blood and products
排除标准
- •Patients who did not have allogeneic bone marrow transplantation
- •Patient dissatisfaction
- •Having an infection or fever above 38.5 ° C before entering the study
研究者
相似试验
进行中（未招募）
3 期
GRAPPA2023-510441-24-00DKMS Group gGmbH640
进行中（未招募）
1 期
Prevention of graft-against-host disease in patients treated with allogeneic stem cell transplantation: Possible role of extracorporeal photophoresisGraft-versus-host disease (GVHD), both acute and chronic untill one year after allogeneic stam cell transplatationEUCTR2017-000614-39-NOOSLO UNIVERSITY HOSPITAL HF156
招募中
2 期
Single agent GVHD prophylaxis with PTCY for SCT: a phase II studyeukemia/lymphomaHematologic malignancyJPRN-jRCTs031180399Sakaguchi Hirotoshi30
招募中
不适用
Single agent graft-versus-host disease prophylaxis with post-transplant cyclophosphamide for stem cell transplantation: a phase II study (SAP-P2)Acute leukemiaJPRN-UMIN000021375ational Center for Child Health and Development30
已完成
1 期
PTCy and Ruxolitinib GVHD Prophylaxis in MyelofibrosisMyeloproliferative DisordersPrimary MyelofibrosisNCT02806375St. Petersburg State Pavlov Medical University20